Therefore, our results suggest that USP22 expression levels alone or combined with HLA-I expression levels and CD8+ T cell infiltration frequency prior to ICB, could serve as a more accurate biomarker to predict the ICB immunotherapeutic response for lung cancer treatment. The gene discussed is CD8A; the disease is lung carcinoma.